|
|
|
|
| LEADER |
05496nam a2200517 4500 |
| 001 |
ocn834598601 |
| 003 |
OCoLC |
| 005 |
20180501122008.0 |
| 006 |
m o d |
| 007 |
cr cn||||||||| |
| 008 |
130228s2013 enkadf ob 001 0 eng d |
| 040 |
|
|
|a E7B
|b eng
|e pn
|c E7B
|d OCLCQ
|d OCLCO
|d UIU
|d N$T
|d OCLCF
|d EBLCP
|d MHW
|d YDXCP
|d DEBSZ
|d OCLCQ
|d UAB
|d GrThAP
|
| 019 |
|
|
|a 828298528
|
| 020 |
|
|
|a 9780123947918
|q (electronic bk.)
|
| 020 |
|
|
|a 012394791X
|q (electronic bk.)
|
| 020 |
|
|
|a 9780123945877
|
| 035 |
|
|
|a (OCoLC)834598601
|z (OCoLC)828298528
|
| 050 |
|
4 |
|a QP552.G16
|b O45 2013eb
|
| 072 |
|
7 |
|a SCI
|x 007000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 572.6/96
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Oligomerization and allosteric modulation in G-protein coupled receptors /
|c edited by Terry Kenakin.
|
| 250 |
|
|
|a 1st ed.
|
| 260 |
|
|
|a Oxford :
|b Academic Press,
|c 2013.
|
| 300 |
|
|
|a 1 online resource (xiii, 471 pages, [8] pages of plates :) :
|b illustrations (some color).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Progress in molecular biology and translational science,
|x 1877-1173 ;
|v v. 115
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Front cover; Oligomerization and Allosteric Modulation in G-Protein Coupled Receptors; Copyright; Contents; Contributors; Preface; Chapter One: Approaches for Probing Allosteric Interactions at 7 Transmembrane Spanning Receptors; 1. Introduction; 2. General Considerations for Assays Designed to Identify and Characterize Allosteric Modulators; 3. General Workflow Used in Identifying and Characterizing Allosteric Modulators; 3.1. High-throughput screening; 3.2. Potency determinations; 3.3. Efficacy determinations; 4. Data Analysis: General Features for Allosteric Interactions.
|
| 505 |
8 |
|
|a 5. Kinetic Assays to Measure Allosteric Interactions at 7TMRs5.1. Fluorescence-based second-messenger assays; 5.2. Calcium mobilization, general principles; 5.3. Thallium flux, general principles; 5.4. Fluorescent probe methodology; 5.5. Alternatives to fluorescence technology; 6. Label-Free Technology; 7. Endpoint Assays; 7.1. cAMP accumulation; 7.2. PI hydrolysis; 7.3. ERK1/2 phosphorylation; 7.4. Arrestin recruitment; 7.5. Transcriptional regulation; 8. Radioligand Binding Assays for Allosteric Interactions; 8.1. General methodology and initial considerations; 8.1.1. Receptor source.
|
| 505 |
8 |
|
|a 8.1.2. Choice of radioligand8.1.3. Experimental conditions; 9. Competitive or Not Competitive; 9.1. Allosteric radioligand competition; 9.2. Orthosteric radioligand competition; 9.3. Dissociation kinetic assays; 10. Conclusions and Future Directions; Acknowledgments; References; Chapter Two: Pharmacology of Metabotropic Glutamate Receptor Allosteric Modulators: Structural Basis and Therapeutic Pote ... ; 1. Introduction; 2. Physiology and Pharmacology of mGlus; 2.1. Advantages and complexities of allosteric modulation; 3. Allosteric Modulation of mGlus.
|
| 505 |
8 |
|
|a 3.1. Quantification of allosteric modulation3.2. Verification of an allosteric mechanism of action; 4. Location of Allosteric Sites; 4.1. Structural features of mGlus; 4.2. Localization of allosteric binding sites; 4.3. Common allosteric sites within and between subtypes; 4.4. Multiple allosteric sites within a receptor subtype; 5. Therapeutic Indications for Allosteric Modulators; 5.1. mGlu1 NAMs for neuropathic pain; 5.2. mGlu2/3 PAMs and agonists for schizophrenia and cognition; 5.3. mGlu2/3 in anxiety; 5.4. mGlu2/3 PAMs for drug abuse; 5.5. mGlu2/3 PAMs for depression.
|
| 505 |
8 |
|
|a 5.6. mGlu4 PAMs for PD and neuroprotection5.7. mGlu4 PAMs in pain and neuroinflammation; 5.8. mGlu5 NAMs for anxiety; 5.9. mGlu5 NAMs for major depression disorder; 5.10. mGlu5 NAMs for Autism; 5.11. mGlu5 NAMs for drug abuse; 5.12. mGlu5 NAMs for potential treatment of astrocytic disorders; 5.13. mGlu5 for treatment of PD, iatrogenic dystonias, gastroesophogeal reflux disorder, and migraine; 5.14. mGlu5 PAMs for schizophrenia and cognition; 5.15. mGlu5 PAMs for treatment of TSC; 5.16. mGlu7 for stress and anxiety; 5.17. mGlu8 potential for the treatment of PD and anxiety.
|
| 520 |
|
|
|a In this thematic volume of Progress in Molecular Biology and Translational Science, researchers reflect on recent developments and research surrounding G protein-coupled receptors. The chapters cover a large breadth of research, including GPCR role in stem cell function and pharmacology. Authors explore in-depth research techniques and applications of GPCR usage, covering theory, laboratory approaches, and unique qualities that make GPCRs a crucial tool in microbiological and cancer research. Key features: * Contributions from leading authorities * Informs an.
|
| 650 |
|
0 |
|a G proteins
|x Receptors.
|
| 650 |
|
0 |
|a Allosteric regulation.
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Biochemistry.
|2 bisacsh
|
| 650 |
|
7 |
|a Allosteric regulation.
|2 fast
|0 (OCoLC)fst00805690
|
| 650 |
|
7 |
|a G proteins
|x Receptors.
|2 fast
|0 (OCoLC)fst00936832
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Kenakin, Terrence P.
|
| 776 |
0 |
8 |
|i Print version:
|a Kenakin, Terry.
|t Oligomerization and Allosteric Modulation in G-Protein Coupled Receptors.
|d San Diego : Elsevier Science, ©2013
|z 9780123945877
|
| 830 |
|
0 |
|a Progress in molecular biology and translational science ;
|v v. 115.
|x 1877-1173
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/18771173/115
|z Full Text via HEAL-Link
|
